Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (306)	3/6/2001 2:07:06 PM
From: thebeach	Read Replies (1) \| Respond to of 356

PROCYON BIOPHARMA INC - Retains Investor Relations Firm - Renmark Financial Communications [222] Canadian Market News from Market News Publishing, Tuesday, March 06, 2001 at 10:13 Procyon BioPharma Inc. ("Procyon") announced that is has retained the services of Renmark Financial Communications Inc. ("Renmark") as their investor relations ("IR") firm, a well known IR firm located in Montreal, Quebec . "We are pleased to announce that Renmark has been chosen to enhance our investor relations function. We believe that Renmark will provide Procyon increased visibility within the financial community by providing our Company with an effective investor relations program," stated Hans J. Mader, President and CEO of Procyon. In consideration of the services to be provided, the Company has agreed to pay a monthly retainer to Renmark Financial Communications. In addition, subject to approval from applicable regulatory authorities, the Company has agreed to grant to Renmark stock options to acquire common shares of Procyon. Procyon BioPharma Inc. is a publicly listed, biopharmaceutical Company focused principally on advancing two powerful platform technologies that have the potential to diagnose and treat cancer. Procyon's non-pathogenic Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly enhancing the immune response to cancer cells. Prostate Secretory Protein PSP(94) is a naturally occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal prostate cell growth. In addition, the estimation of PSP(94) levels in prostate cancer patients may have prognostic and diagnostic applications. Procyon also has two late-stage products: FIBROSTAT(TM) and COLOPATH(TM) a rapid, non-invasive screening test for colorectal cancer. Procyon's shares trade on the Toronto Stock Exchange under the ticker symbol PBP. TEL: (514)-685-9283 Procyon BioPharma Inc. Hans Mader, President & CEO EMAIL: hmader@procyonbiopharma.com INET : www.procyonbiopharma.com TEL: (514)-843-2309 NATIONAL Public Relations Nathalie Bourque (Public Relations) TEL: (514) 939-3989 Renmark Financial Communications Inc. John Stella (Investors Relations) EMAIL: jstella@renmarkfinancial.com INET : www.renmarkfinancial.com TEL: (514) 939-3989 Renmark Financial Communications Inc. John Boidman (Investors Relations) EMAIL: jboidman@renmarkfinancial.com INET : www.renmarkfinancial.com (c) Market News Publishing Inc. Tel:(604) 689-1101 All rights reserved. Fax:(604) 689-1106 MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041.